利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

158 条记录 (耗时 0.031 秒)

    Time Delay Mechanism for a Hydraulic Drug Delivery Device
    96.
    发明申请
    Time Delay Mechanism for a Hydraulic Drug Delivery Device 有权

    公开(公告)号：US20220160959A1

    公开(公告)日：2022-05-26

    申请号：US17670262

    申请日：2022-02-11

    申请人： Zealand Pharma A/S

    发明人： Christopher Gregory ,  Geoffrey Jenkins

    IPC分类号： A61M5/142 ,  A61M5/145 ,  A61M5/32

    摘要： A medicament delivery device may comprise a medicament chamber configured to hold a medicament, a plunger configured to move relative to the medicament chamber to expel the medicament from the medicament chamber, a pin configured to move from a first pin position wherein the pin prevents movement of the plunger to a second pin position wherein the pin allows movement of the plunger, an actuation assembly configured to move the pin from the first pin position to the second pin position, and a needle coupled to the medicament chamber. The medicament may flow through the needle from the medicament chamber to a user. The actuation assembly may be configured to automatically move the pin after a predetermined time delay.

    FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES
    99.
    发明申请
    FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES 有权

    公开(公告)号：US20220031810A1

    公开(公告)日：2022-02-03

    申请号：US17279691

    申请日：2019-09-27

    申请人： Zealand Pharma A/S

    发明人： Henrik Rajesh Kumar PARSHAD ,  Lise GIEHM ,  Claes MELANDER

    IPC分类号： A61K38/26 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  A61K9/08

    摘要： Liquid formulations of GLP-2 analogues are described that make it possible to include a preservative while allowing the formulation to be stabilised for long term storage as liquids and/or as multi-dose liquid formulations. The development of these formulations is base on the finding that that reducing the pH of the formulation to below 7.0, e.g. to a pH between about pH 5.0 and about 6.8, was able to offset the effect that the addition of a preservative such as meta-cresol has on the physical stability of the formulation. Additionally, the addition of an excipient such as propylene glycol was shown to be able to offset the effect that the addition of a preservative, such as meta-cresol, has on the physical stability of the formulation. This opens up the possibility of being able to deliver the GLP-2 analogues as multi-dose formulations, for example allowing the use of the formulations in a drug delivery device.